Numinus and Multidisciplinary Association for Psychedelic Studies collaboration will conduct follow-on Compassionate Access trial in real-world setting in Vancouver, Canada VANCOUVER, May 10, 2021 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies…


Previous articleWesana Health Commences Trading on the CSE
Next articlePsychedelics Today’s 5th Birthday Party